Postdoc researcher
PhD Sherif Bayoumy, PhD - postdoc
Research:
I specialize in immunoassay technologies, optimizing biomarker detection for clinical applications while ensuring analytical and regulatory rigor. My PhD research focused on fluid biomarkers for neurological diseases, particularly Alzheimer’s disease and pediatric spinal muscular atrophy (SMA). I developed and validated novel immunoassays for key biomarkers, including hyperphosphorylated tau, amyloid beta, beta-synuclein, and neurofilament light chain, and contributed to a successful qualification opinion submission to the European Medicines Agency (EMA) for SMA biomarkers. While experienced across various assay platforms, my main interest lies in ultrafast and portable diagnostics to improve healthcare accessibility. This passion stems from my drive to make healthcare more accessible globally. My current research advances point-of-care (PoC) testing, integrating biomarker-driven diagnostics into clinical workflows.
Curriculum Vitae:
I earned my Bachelor's in Pharmaceutical Sciences from Cairo University in 2013. After joining Nestlé Egypt in 2014 to work on pathogen monitoring with immunoassays, I pursued a Master’s in Biotechnology at the University of Turku, developing a rapid hepatitis C test and gaining experience at PerkinElmer in prenatal screening. In 2018, I led the development of two novel rapid tests for myocardial infarction and ovarian cancer at the Pettersson Lab. I received an international innovation award for development of the rapid ovarian cancer test in 2020. In the same year, I began my Marie Skłodowska-Curie PhD at Amsterdam UMC under Prof. Charlotte Teunissen, focusing on fluid biomarkers for neurological diseases. My research included a secondment at ADx Neurosciences (Fujirebio Europe). In 2025, I joined the Conrstjens Lab to further explore point of care assays for various disease indications.
https://doi.org/10.1186/s13195-021-00939-9
Publications
-
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231;
Bayoumy, S., Verberk, I.M.W., den Dulk, B. et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alz Res Therapy 13, 198 (2021).
https://doi.org/10.1186/s13195-021-00939-9
-
A Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125
Bayoumy, S., Hyytiä, H., Leivo, J. et al. Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125. Commun Biol 3, 460 (2020).
https://doi.org/10.1038/s42003-020-01191-x
-
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
Bellomo G, Bayoumy S, Megaro A, et al. Alzheimer's Dement. 2024; 20: 2453–2468.
https://doi.org/10.1002/alz.13687
